PubMed Health⌕ Search

Biomedical subjects

J Kemmler

Publications and source records attributed to J Kemmler.

17 recordsLinked to original sources
PubMed1990

Isolation and growth of a bacterium able to degrade nitrilotriacetic acid under denitrifying conditions.

A Gram-negative bacterium was isolated from river sediment which was able to grow with nitrilotriacetic acid as a combined carbon, nitrogen and energy source in the absence of molecular oxygen using nitrate as the terminal electron acceptor. Batch growth parameters and mass balances are reported for growth under both aerobic and denitrifying conditions. The strain was characterized with respect to its substrate spectrum and other physiological properties. This denitrifying isolate is serologically unrelated to the comprehensively described Gram-negative obligately aerobic NTA-degrading bacteria all of which belong to the alpha-subclass of Proteobacteria. Chemotaxonomic characterization, which revealed the presence of spermidine as the main polyamine and ubiquinone Q-8, excludes the new isolate from the phylogenetically redefined genus Pseudomonas and indicates a possible location within the gamma-subclass of Proteobacteria close to, but separate from the genus Xanthomonas.

Biodegradation, Environmental↗
PubMed1989

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

We tested the clinical efficacy of a biologically active dose (BAD) of interferon (IFN)-gamma for treatment of progressive renal cell carcinoma (RCC). Twenty-two RCC patients with disease progression subsequent to nephrectomy were entered on a phase II clinical trial. During an initial dose-finding phase, biochemical responses to repeated once-weekly subcutaneous injections of 10, 100, or 500 micrograms of recombinant IFN-gamma were tested in 16 patients. Results indicated that 100 micrograms IFN-gamma applied once weekly was biologically active with induction of serum beta 2-microglobulin and neopterin. Such a dose induced a nearly maximum response of both markers lasting more than 4 days. This dose was also associated with minimal side effects. A dose of 100 micrograms IFN-gamma given once weekly was, therefore, subsequently given weekly for long-term treatment. During a median time of therapy of 10 months (range, 2 to 32 months) two complete (CR; 20+, 20+ months) and four partial tumor responses (PR; 6+, 7+, 8+, 24+ months) were seen (30% CR plus PR; 95% confidence limits, 12% to 54%) among 20 patients evaluable for response. Patients with refractory disease had significantly lower IFN-gamma-induced increments of serum beta 2-microglobulin than those who achieved clinical remission or stable disease.

Adult↗